The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Good morning dealmakers, it’s Obey Martin Manayiti with the US edition of the Wire from the New York newsroom, filling in for ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Detailed price information for Avid Bioservices Inc (CDMO-Q) from The Globe and Mail including charting and trades.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, ...

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and ...